Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity
- PMID: 12791936
- PMCID: PMC156485
- DOI: 10.1128/JCM.41.6.2795-2796.2003
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity
References
-
- Baquero, F. 1997. Gram-positive resistance: challenge for the development of new antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):1-6. - PubMed
-
- Candiani, G., M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti. 1999. In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192. - PubMed
-
- Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin: United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567. - PubMed
-
- Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254. - PubMed
-
- National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
